Joint Clinical Trials Office
A Phase 1b/2, Multicenter, Randomized, Open-Label Study to Evaluate The Efficacy And Safety Of GSK5764227 Alone And In Combination In Participants With Previously Treated Advanced Unresectable Or Metastatic Gastrointestinal Solid Tumors
Study Status:
Open to Enrollment
Primary Investigator:
Date: February 6, 2026
A Randomized Study Evaluating 2 Dose Regimens of Dupilumab in Children ≥6 Months of Age Weighing ≥5 to <15 kg With Active Eosinophilic Esophagitis
Study Status:
Open to Enrollment
Primary Investigator:
Date: February 9, 2026
Pulmonary Segmentectomy for Lung Cancer: A Real-World International Registry-TSOG 108
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 9, 2026
A Phase 3 randomized open-label study of belantamab mafodotin in combination with lenalidomide and dexamethasone versus daratumumab, lenalidomide, and dexamethasone in participants with newly diagnosed multiple myeloma who are ineligible for auto-SCT
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 11, 2026
Prospective randomized study of the Kono-S anastomosis versus the side-to-side functional end anastomosis in the prevention of post-operative recurrence of Crohn’s disease
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 30, 2026
GS-US-567-6968: Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 31, 2026
FMT and Other Gut Microbial Therapies National Registry: Acute Severe and Fulminant C. Difficile Infection
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 31, 2026
Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutated or KMT2A Rearranged AML
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 31, 2026
The underappreciated role of atherosclerotic cardiovascular disease in primary biliary cholangitis
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 16, 2026
A Phase III, Multisite, Double-Blinded Randomized Trial of BNT327 In Combination with Chemotherapy (Etoposide/Carboplatin) Compared to Atezolizumab In Combination with Chemotherapy In Participants with First-Line Extensive-Stage Small-Cell Lung Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 31, 2026